Logo image of NSRX

NASUS PHARMA LTD (NSRX) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:NSRX - IL0012181553 - Common Stock

6.25 USD
-0.38 (-5.71%)
Last: 1/23/2026, 8:24:22 PM
Fundamental Rating

1

NSRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. NSRX may be in some trouble as it scores bad on both profitability and health. NSRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year NSRX has reported negative net income.
  • NSRX had a negative operating cash flow in the past year.
NSRX Yearly Net Income VS EBIT VS OCF VS FCFNSRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -1K -2K -3K -4K

1.2 Ratios

  • With a Return On Assets value of -442.86%, NSRX is not doing good in the industry: 95.81% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -442.86%
ROE N/A
ROIC N/A
ROA(3y)-605.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NSRX Yearly ROA, ROE, ROICNSRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • NSRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NSRX Yearly Profit, Operating, Gross MarginsNSRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

  • The number of shares outstanding for NSRX remains at a similar level compared to 1 year ago.
  • NSRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NSRX Yearly Shares OutstandingNSRX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
NSRX Yearly Total Debt VS Total AssetsNSRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200 400 600

2.2 Solvency

  • NSRX has an Altman-Z score of 9146.94. This indicates that NSRX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of NSRX (9146.94) is better than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 9146.94
ROIC/WACCN/A
WACCN/A
NSRX Yearly LT Debt VS Equity VS FCFNSRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 -1K -2K -3K

2.3 Liquidity

  • NSRX has a Current Ratio of 0.13. This is a bad value and indicates that NSRX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of NSRX (0.13) is worse than 96.34% of its industry peers.
  • A Quick Ratio of 0.13 indicates that NSRX may have some problems paying its short term obligations.
  • NSRX has a Quick ratio of 0.13. This is amonst the worse of the industry: NSRX underperforms 95.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
NSRX Yearly Current Assets VS Current LiabilitesNSRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1K 2K 3K 4K

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for NSRX have decreased strongly by -50.00% in the last year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NSRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -1488.99% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-232800%
EPS Next 2Y-5701.72%
EPS Next 3Y-1488.99%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NSRX Yearly EPS VS EstimatesNSRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Forward Price/Earnings Ratio is negative for NSRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSRX Price Earnings VS Forward Price EarningsNSRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSRX Per share dataNSRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as NSRX's earnings are expected to decrease with -1488.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5701.72%
EPS Next 3Y-1488.99%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for NSRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NASUS PHARMA LTD / NSRX FAQ

What is the ChartMill fundamental rating of NASUS PHARMA LTD (NSRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NSRX.


What is the valuation status for NSRX stock?

ChartMill assigns a valuation rating of 0 / 10 to NASUS PHARMA LTD (NSRX). This can be considered as Overvalued.


Can you provide the profitability details for NASUS PHARMA LTD?

NASUS PHARMA LTD (NSRX) has a profitability rating of 0 / 10.


What is the expected EPS growth for NASUS PHARMA LTD (NSRX) stock?

The Earnings per Share (EPS) of NASUS PHARMA LTD (NSRX) is expected to decline by -232800% in the next year.